Taiwan-based HealthTech startup, iWEECARE has raised US$ 2.4M in an extended Series A funding round held in September 2020, led by TransLink Capital along with participation from Taiwan’s National Development Fund, BE Capital, Taiwan Surface Mounting Technology Corp, NCTU Angel Club, Might Electronic, and existing investors Verge HealthTech Fund (Singapore) and Darwin Venture (Taiwan).
Capital raised will be used by iWEECARE to enhance its marketing activities to cater to the increasing demand for remote patient monitoring technologies in the US and China.
Founded in 2014 by Glen Tseng, iWEECARE is the creator of the world’s most comprehensive and convenient thermometer called Temp Pal®.
About Temp Pal
Temp Pal® is a CE (Conformitè Europëenne) medical device certified, modernized, soft, wearable thermometer that continuously measures temperature and sends temperature readings to a smartphone or tablet wirelessly. Unlike traditional thermometers, it is small and flexible, child-friendly and does its job while the patient is sleeping. iWEECARE has partnered with electronics manufacturers and TSMT (Taiwan Surface Mounting Technology) to develop this thermometer. Its team members comprise of parents and couples expecting a child, who at the same time have experienced the hassles of checking BBT (Basic Body Temperature) chart and restless nights worrying about their child’s fever. Hence, they combined their engineering and medical expertise to develop Temp Pal®, a device designed to make temperature measuring easier and more comfortable.
The product has received medical accreditation in Europe, Singapore, Thailand, and Taiwan. As mentioned in the startup’s press release, Temp Pal is already being used in China, Ireland, Japan, Thailand, and Taiwan as a solution to reduce the risk of COVID-19 infection and reduce the load on health systems by decreasing the physical contact between doctors/nurses and their patients.
CEO Glen Tseng was quoted to say, “Temp Pal received an overwhelming amount of inquiries for coronavirus use from the US and China earlier this year. The new funding will be used in accelerating our global footprint to satisfy the demands from these markets and ultimately improve patient safety and outcomes.”
The startup had obtained US$ 1M in a pre-Series A funding round held in June 2019 from Singapore’s Verge HealthTech Fund, TransLink Capital and Darwin Venture.
About TransLink Capital
TransLink Capital is an early-stage venture capital firm based in Palo Alto, USA. The startup’s aim is to collaborate with US-based entrepreneurs and help them in identifying and accessing strategic partners by leveraging the firm’s exclusive understandings and connections. Its portfolio of companies includes Foxconn, Hikari Tsushin, SoftBank and UMC.
We try our best to fact check and bring the best, well-researched and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!
[…] Next Story. […]